

In the Claims:

Kindly amend the claims as follows:

1. to 5.	[Cancelled]
6.	[Previously Cancelled]
7.	[Cancelled]
8.	[Previously Cancelled]
9. to 12.	[Cancelled]

13. (New) A drug delivery composition for nasal administration comprising a solution comprising chitosan, and ICAM-1, wherein the ICAM-1 is present in the composition in a concentration between about 0.01 and 20% by weight per volume; wherein the composition is adapted to deliver to the nasal cavity an antivirally effective amount of ICAM-1.

C
2 14. (New) The drug delivery composition of claim 13, wherein the chitosan is present in the solution in a concentration of 0.2 to 2.0% weight per volume.

15. (New) The composition of claim 13, wherein the chitosan is present in the solution in a concentration of 0.1% to 15% weight per volume.

16. (New) The drug delivery composition of claim 13, wherein the ICAM-1 is present in the composition in a concentration in the range of 0.2 to 5% weight per volume.

17. (New) A drug delivery composition for nasal administration comprising a plurality of microspheres comprising a material selected from the group consisting of starch, chitosan, gelatin, hyaluronic acid, alginate, and gellan, and ICAM-1, wherein the ICAM-1 is present in the microspheres in an amount of between about 0.1 and 50% by weight of the microspheres;

wherein the composition is adapted to deliver to the nasal cavity an antivirally effective amount of ICAM-1.

18. (New) The composition of claim 17, wherein the ICAM-1 is incorporated into the microsphere in an amount of 1 to 20% by weight of the microspheres.

C₂

19. (New) A method of delivering ICAM-1 to the nasal cavity to increase its effectiveness comprising

administering a composition comprising a bioadhesive material and ICAM -1, wherein the bioadhesive material is selected from the group consisting of a liquid formulation comprising chitosan and a plurality of microspheres, the microsphere comprising a material selected from the group consisting of starch, chitosan, gelatin, hyaluronic acid, alginate, and gellan,

wherein the composition is adapted to deliver to the nasal cavity an antivirally effective amount of ICAM-1.
